Full Press Release Details
Biosciences, Inc. Announces Research and Development Collaboration with Scripps Research to Advance XCART Platform
Represents significant milestone in strategic development plan to advance XCART through academic collaborations -
Provides access to leading research institution with world renowned immunology expertise -
Company engaged in ongoing discussions to potentially add additional academic and development collaborators -
MA - (May 19, 2020) - Xenetic Biosciences, Inc. (NASDAQ: XBIO)
("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART , a personalized
CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today it has entered into a research
funding and option agreement ("the Agreement") with Scripps Research to advance the development of the XCART
technology for B cell malignancies.
is a significantly differentiated, proprietary approach to personalized CAR T therapy for the treatment of multiple tumor types
of B-cell Non-Hodgkin lymphomas, and was originally developed by Scripps Research in collaboration with the Shemyakin-Ovchinnikov
Institute of Bioorganic Chemistry. XCART is believed to have the potential to significantly enhance the safety and efficacy of
cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells.
"We are thrilled to partner with
Scripps Research to aid in the development of XCART. Not only are they a leading, world renowned research and development organization,
but they are also one of the original developers of the XCART platform," commented Jeffrey Eisenberg, Chief Executive Officer
of Xenetic. "We believe that the team at Scripps Research, given their deep knowledge and understanding of the XCART platform,
is uniquely qualified to guide key aspects of our preclinical development program. They will also provide method development expertise
as the program moves towards process development for clinical manufacturing. We expect this collaboration to be one of the integral
elements in our strategy of leveraging academic and development partners to provide operational efficiencies as we drive XCART
toward clinical manufacturing and ultimately first-in-human studies."
The XCART technology platform was designed
to utilize an established screening technique to identify polypeptide domains that selectively bind to the unique B-cell receptor
("BCR") on the surface of an individual lymphoma patient's malignant B-cell clones. This BCR-selective targeting
domain is engineered into the antigen-binding domain of a chimeric antigen receptor ("CAR"), creating the possibility
of a CAR T treatment that should only recognize a given patient's malignant B-cell clones. An expected result for XCART is
limited off-tumor toxicities, such as B-cell aplasia. Xenetic's clinical development program will seek to confirm the early
preclinical results, and to demonstrate a more attractive safety profile than existing therapies.
"We are pleased to enter this agreement
with Xenetic to participate in the preclinical development of the XCART platform. Our past experience with the technology will
suit us well as we work closely with the Xenetic team to advance this platform for B cell malignancies," added Dr. Richard
Lerner, Lita Annenberg Hazen Professor of Immunochemistry at Scripps Research.
Under the terms of the Scripps Research
agreement, Xenetic will be granted an exclusive license to certain intellectual property arising from the research program in the
field of B-cell malignancies, as well as an option to acquire rights and licenses to new intellectual property outside of that
field. Xenetic is actively engaged in ongoing discussions to advance the development of XCART through additional collaborations
with academic or development partners.
Scripps Research is an independent, nonprofit
biomedical institute ranked the most influential in the world for its impact on innovation. With campuses in La Jolla, California,
and Jupiter, Florida, we are advancing human health through profound discoveries that address pressing medical concerns around
Our drug discovery and development division,
Calibr, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as
possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics
to understand individual health and render more effective healthcare.
Scripps Research also trains the next generation
of leading scientists at our Skaggs Graduate School, consistently named among the top 10 U.S. programs for chemistry and biological
sciences. Learn more at http://www.scripps.edu.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART , a personalized CAR T platform technology
engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting
the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas.
XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Additionally, Xenetic is leveraging PolyXen , its proprietary drug delivery platform, by partnering with biotechnology and
pharmaceutical companies. PolyXen has demonstrated its ability to improve the half-life and other pharmacological properties
of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field
of coagulation disorders and receives royalty payments under this agreement.
For more information, please visit the Company's website at www.xeneticbio.com
and connect on Twitter, LinkedIn, and Facebook.
This press release contains forward-looking
statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements
contained in this press release other than statements of historical facts may constitute forward-looking statements within the
meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans,"
"projects," "will," "may," "anticipates," "believes," "should," "intends,"
"estimates," and other words of similar meaning, including, but not limited to, statements regarding the Company's
active engagement in discussions to advance the development of XCART through additional collaborations with academic or development
partners, the belief that XCART has the potential to significantly enhance the safety and efficacy of cell therapy for B-cell
lymphomas by generating patient- and tumor-specific CAR T cells, the Company's belief that securing academic collaborations
to develop XCART provides many advantages, the Company's belief that the Scripps Research team is uniquely qualified to
guide key aspects of the Company's preclinical development program, anticipations that Scripps Research will provide method
development expertise as the program moves towards process development for clinical manufacturing, the Company's expectations
that the collaboration with Scripps Research will be one of the integral elements in the Company's strategy of leveraging
academic and development partners to provide operational efficiencies as the Company drives XCART toward clinical manufacturing
and first-in-human studies, expected results for XCART to include limited off-tumor toxicities, such as B-cell aplasia, expectations
that the Company's clinical development program will confirm the early preclinical results and demonstrate a more attractive
safety profile than existing therapies, expectations that Scripps Research past experience with the XCART technology will suit
Scripps Research well as part of the collaboration, the expected results of the agreement with Scripps Research, including anticipated
grants of intellectual property licenses under the agreement, the Company's plans to initially apply the XCART technology
to advance cell-based therapeutics by targeting the unique B-cell receptor on the surface of an individual patient's malignant
tumor cells for the treatment of B-cell lymphomas, the Company's expectations that XCART has the potential to fuel a robust
pipeline of therapeutic assets targeting high-value oncology indications, the Company's plans to leverage PolyXen by
partnering with biotechnology and pharmaceutical companies, and the Company's expectation regarding receipt of royalty payments
under the exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. Any forward-looking statements contained herein are
based on current expectations, and are subject to a number of risks and uncertainties. Many factors could cause our actual activities,
performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements.
Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans,
estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from the acquisition of XCART;
(2) uncertainty of the expected financial performance of the Company following completion of the acquisition of XCART; (3) failure
to realize the anticipated potential of the XCART technology; (4) the ability of the Company to implement its business strategy;
and (5) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual
report on Form 10-K, periodic quarterly reports on Form 10-Q, periodic current reports on Form 8-K and other documents filed with
the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely
affected by general market factors, general economic and business conditions, including potential adverse effects of public health
issues, such as the COVID-19 outbreak on economic activity, competitive product development, product availability, federal and
state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that
may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release
speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking
statements, except as required by law.